A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

April 30, 2021

Study Completion Date

August 1, 2023

Conditions
Neoplasms
Interventions
DRUG

BI 754091

Trial Locations (13)

29605

Greenville Health System, Greenville

34232

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, PLLC, Nashville

48201

Karmanos Cancer Institute, Detroit

60426

Ingalls Memorial Hospital, Harvey

73104

Stephenson Cancer Center, Oklahoma City

77030

The University of Texas MD Anderson Cancer Center, Houston

L8V 5C2

Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton

K1H 8L6

The Ottawa Hospital, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H2X 0A9

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal

W1G 6AD

Sarah Cannon Research Institute, London

M20 4BX

The Christie Hospital, Manchester

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY